



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 19th, 2015 6:00 – 8:30 p.m.

- 1. Executive Session** **6:00 - 6:30**

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:40**
 - Updates

- 4. Medical Director Update** **6:40 – 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:45 – 7:00**
 - Multiple benzo analysis including sedative/hypnotic(Z drugs)-
Z drugs quantity limits
 - Advair Diskus Criteria
 - Updated GI Agents Criteria- dicyclomine

- 6. RetroDUR/DUR** **7:00 – 7:20**
 - 2016 RetroDUR Initiatives

- 7. Clinical Update: Drug Reviews** **7:20 – 7:45**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Harvoni® Tab (ledipasvir & sofosbuvir combination)
 - Technivie® Tab (ombitasvir/paritaprevir/ritonavir)
 - Viekira® Pak (ombitasvir, paritaprevir & ritonavir tabs; dasabuvir tabs)

 - Full New Drug Reviews**
 - Rexulti® Tab (brexpiprazole)
 - Entresto® Tab(valsartan/sacubitril)

- 8. Therapeutic Drug Classes – Periodic Review** **7:45 – 8:15**
(Public comment prior to Board action)
 - Acne
 - Antibiotics, GI

- Antibiotics, Misc
- Cephalosporins
- Fluoroquinolones
- Tetracyclines

9. New Managed Therapeutic Drug Classes **8:15 – 8:15**
 (Public comment prior to Board action)

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products **8:15 – 8:15**
 (Public comment prior to Board action)

11. General Announcements **8:15 – 8:30**
Selected FDA Safety Alerts

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA announces Glades Drugs' nationwide voluntary recall of Compounded Multivitamins containing High Amounts of Vitamin D3 (Cholecalciferol)

<http://www.fda.gov/drugs/drugsafety/ucm474552.htm>

FDA takes action to protect consumers from potentially dangerous dietary supplements

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473099.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA advises of rare cases of underactive thyroid in infants given iodine-containing contrast agents for medical imaging

http://www.fda.gov/Drugs/DrugSafety/ucm472782.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

12. Adjourn **8:30**